Mostrar el registro sencillo del ítem
Acute consumption of p-synephrine does not enhance performance in sprint athletes
dc.contributor.author | Gutiérrez, Jorge | |
dc.contributor.author | Salinero, J.J. | |
dc.contributor.author | Abián-Vicen, J. | |
dc.contributor.author | Areces, F. | |
dc.contributor.author | Lara, B | |
dc.contributor.author | Gallo-Salazar, C. | |
dc.contributor.author | Puente, Carlos | |
dc.contributor.author | Del Coso, J. | |
dc.date.accessioned | 2017-09-08T10:36:33Z | |
dc.date.available | 2017-09-08T10:36:33Z | |
dc.date.issued | 2016-06 | |
dc.identifier.other | http://www.nrcresearchpress.com/doi/abs/10.1139/apnm-2015-0299?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&#citart1 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.12020/400 | |
dc.description.abstract | P-Synephrine is a protoalkaloid widely used as an ergogenic aid in sports. This substance has been included in the World Anti-Doping Agency monitoring program, although scientific information about its effects on performance and athletes' well-being is scarce. The purpose of this investigation was to determine the effectiveness of p-synephrine to increase performance in sprint athletes. In a randomized and counterbalanced order, 13 experienced sprinters performed 2 acute experimental trials after the ingestion of p-synephrine (3 mg·kg(-1)) or after the ingestion of a placebo (control trial). Forty-five minutes after the ingestion of the substances, the sprinters performed a squat jump, a countermovement jump, a 15-s repeated jump test, and subsequently performed 60-m and 100-m simulated sprint competitions. Self-reported questionnaires were used to assess side-effect prevalence. In comparison with the control trial, the ingestion of p-synephrine did not change countermovement jump height (37.4 ± 4.2 vs 36.7 ± 3.3 cm, respectively; P = 0.52), squat jump height (34.4 ± 3.6 vs 33.9 ± 3.7 cm; P = 0.34), or average 15-s repeated jumps height (31.8 ± 4.1 vs 32.2 ± 3.6 cm; P = 0.18). P-Synephrine did not modify maximal running speed during the 60-m (9.0 ± 0.5 vs 9.0 ± 0.4 m·s(-1), respectively; P = 0.55) and 100-m sprint competitions (8.8 ± 0.5 vs 8.8 ± 0.5 m·s(-1), respectively; P = 0.92). The ingestion of p-synephrine did not alter the prevalence of headache, gastrointestinal discomforts, muscle pain, or insomnia during the hours following the tests. Acute consumption of 3 mg·kg(-1) of p-synephrine was ineffective to increase performance in competitive sprint athletes. Moreover, p-synephrine did not increase the occurrence of side effects after the competition. | es |
dc.language.iso | en | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Acute consumption of p-synephrine does not enhance performance in sprint athletes | es |
dc.type | article | es |
dc.identifier.doi | 10.1139/apnm-2015-0299 | |
dc.issue.number | 1 | es |
dc.journal.title | Applied Physiology, Nutrition, and Metabolism | es |
dc.page.initial | 63 | es |
dc.page.final | 69 | es |
dc.rights.accessRights | embargoedAccess | es |
dc.subject.area | Ciencias de la Actividad Física y del Deporte | es |
dc.subject.unesco | 3201.99 Otras | |
dc.volume.number | 41 | es |
Ficheros en el ítem
Fichero/s | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |